Sort   by:  
 Page size 
ProteomicsProteomics of Human Hepatoma Huh-7 Cells Treated by Three Multi-RTK Inhibitors
Sorafenib, lenvatinib and regorafenib, the multi-RTK inhibitors with potent anti-angiogenesis effects, are currently therapeutic drugs generally recommended for the patients with advanced hepatocellular carcinoma (HCC). To date, however, there have been no published studies on the mechanism underlin...
ORGANISM(S): Homo sapiens (Human) 
2022-10-13 | PXD034073 | Pride
Huh-7 cells Proteomics Multi-rtk inhibitors 
UnknownCell-cycle and apoptosis related and proteomics-based signaling pathways of human hepatoma Huh-7 cells treated by three currently used multi-RTK inhibitors.
Not available
S-EPMC9444053 | biostudies-literature
TranscriptomicsRNA-seq to investigate impact of treatment of KRAS mutant NCI-H2009 lung adenocarcinoma cells with the multi-ERBB inhibitor Neratinib
KRAS mutation is widely presumed to confer independence from upstream RTK signalling, however emerging evidence from mouse models of lung cancer suggests that ERBB RTKs may amplify signalling through RAS isoforms and participate in mutant RAS-driven lung cancer. This is one of 3 datasets where we e...
ORGANISM(S): Homo sapiens 
2018-06-01 | E-MTAB-6486 | biostudies-arrayexpress
TranscriptomicsRNA-seq to investigate impact of treatment of KRAS mutant NCI-H358 lung adenocarcinoma cells with the multi-ERBB inhibitor Neratinib
KRAS mutation is widely presumed to confer independence from upstream RTK signalling, however emerging evidence from mouse models of lung cancer suggests that ERBB RTKs may amplify signalling through RAS isoforms and participate in mutant RAS-driven lung cancer. This is one of 3 datasets where we e...
ORGANISM(S): Homo sapiens 
2018-06-01 | E-MTAB-6485 | biostudies-arrayexpress
TranscriptomicsRNA-seq to investigate impact of treatment of KRAS mutant A549 lung adenocarcinoma cells with the multi-ERBB inhibitor Neratinib
KRAS mutation is widely presumed to confer independence from upstream RTK signalling, however emerging evidence from mouse models of lung cancer suggests that ERBB RTKs may amplify signalling through RAS isoforms and participate in mutant RAS-driven lung cancer. This is one of 3 datasets where we e...
ORGANISM(S): Homo sapiens 
2018-06-01 | E-MTAB-6483 | biostudies-arrayexpress
UnknownSmall-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies.
Not available
S-EPMC4159824 | biostudies-literature
UnknownRecent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma.
Not available
S-EPMC10040783 | biostudies-literature
UnknownBroad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer.
Not available
S-EPMC6407678 | biostudies-literature
UnknownDiscovery and evaluation of triple inhibitors of VEGFR-2, TIE-2 and EphB4 as anti-angiogenic and anti-cancer agents.
Not available
S-EPMC5739597 | biostudies-literature
UnknownSystems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition.
Not available
S-EPMC6244947 | biostudies-literature
Sort   by:  
 Page size